Curis biotechnologies LLP was founded in early 2017 with a vision to provide better healthcare options in Oncology as well as Critical Care segment of Pharmaceutical Industry. It is a part of 350 cr group SRE India Which was founded in 2000 by Mr. Sanjeev Pratap Singh and is a leading business conglomerate in the country providing services in construction, infrastructure, real estate, financial services, corporate leasing, Investments Advisory & Market research & Analytics.
CURIS BIOTECH is headed by Mr. Anandhasaynam Aravamuthan who has 22 years of diverse & rich experience of working in pharmaceutical industry especially in Oncology & Critical Care division. He has worked for leading Indian companies like Unimark Remedies, Ozone Pharma, Basikos Pharma etc.
At CURIS, we believe in giving our best for the welfare of society by making quality medicines at affordable prices. In just 2 years, CURIS has established as one of the leading pharmaceutical company with wings spread in many states of India as well as by collaborating with international companies.
CURIS is emerging as the most preferred partner in the Indian healthcare market with unique self differentiation strategies. We are a professional organization with concrete and humane infrastructure to focus in acute as well as chronic care segments and oncology segments guided by the principles of Management by objectives & scientific business techniques. We are determined to develop effective strategies for the production & supply of formulations, specially the life saving drugs at a reasonable price.